Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mukta Arora

Showing results (21-30 of 168) with videos related to

Pageof 17
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2010
Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phaseJohn M Goldman, Navneet S Majhail, John P Klein, et al.
British Journal of Haematology|April 27, 2007
Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemiaSergio A Giralt, Mukta Arora, John M Goldman, et al.
Leukemia & Lymphoma|March 18, 2024
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT studyAurore Perrot, Sosana Delimpasi, Emmanouil Spanoudakis, et al.
Blood Advances|February 9, 2021
Low 5-year health care burden after umbilical cord blood transplantationJesus Garcia Garcia, Sonya Grillo, Qing Cao, et al.
Haematologica|May 26, 2022
Durable discontinuation of systemic therapy in patients affected by chronic graft-<i>versus</i>-host diseaseGeorge L Chen, Lynn Onstad, Paul J Martin, et al.
Transplantation and Cellular Therapy|May 16, 2022
Steroid-Sensitive, but Not Steroid-Dependent or Steroid-Resistant Acute Graft-versus-Host Disease, Results in Similar Infection Risk as No Graft-versus-Host Disease following Allogeneic Hematopoietic Cell TransplantationJo-Anne H Young, Najla El Jurdi, Ahmad Rayes, et al.
Blood|January 17, 2015
Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantationShernan G Holtan, Todd E DeFor, Aleksandr Lazaryan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 18, 2018
Comprehensive B Cell Phenotyping Profile for Chronic Graft-versus-Host Disease DiagnosisJacob Rozmus, Amina Kariminia, Sayeh Abdossamadi, et al.
Blood Advances|March 3, 2021
Steroid-dependent acute GVHD after allogeneic hematopoietic cell transplantation: risk factors and clinical outcomesNajla El Jurdi, Ahmad Rayes, Margaret L MacMillan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 2, 2013
Hand grip strength and 2-minute walk test in chronic graft-versus-host disease assessment: analysis from the Chronic GVHD ConsortiumJoseph Pidala, Xiaoyu Chai, Paul Martin, et al.
Pageof 17

Showing results (21-30 of 168) with videos related to

Sort By:
Pageof 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2010
Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phaseJohn M Goldman, Navneet S Majhail, John P Klein, et al.
British Journal of Haematology|April 27, 2007
Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemiaSergio A Giralt, Mukta Arora, John M Goldman, et al.
Leukemia & Lymphoma|March 18, 2024
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT studyAurore Perrot, Sosana Delimpasi, Emmanouil Spanoudakis, et al.
Blood Advances|February 9, 2021
Low 5-year health care burden after umbilical cord blood transplantationJesus Garcia Garcia, Sonya Grillo, Qing Cao, et al.
Haematologica|May 26, 2022
Durable discontinuation of systemic therapy in patients affected by chronic graft-<i>versus</i>-host diseaseGeorge L Chen, Lynn Onstad, Paul J Martin, et al.
Transplantation and Cellular Therapy|May 16, 2022
Steroid-Sensitive, but Not Steroid-Dependent or Steroid-Resistant Acute Graft-versus-Host Disease, Results in Similar Infection Risk as No Graft-versus-Host Disease following Allogeneic Hematopoietic Cell TransplantationJo-Anne H Young, Najla El Jurdi, Ahmad Rayes, et al.
Blood|January 17, 2015
Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantationShernan G Holtan, Todd E DeFor, Aleksandr Lazaryan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 18, 2018
Comprehensive B Cell Phenotyping Profile for Chronic Graft-versus-Host Disease DiagnosisJacob Rozmus, Amina Kariminia, Sayeh Abdossamadi, et al.
Blood Advances|March 3, 2021
Steroid-dependent acute GVHD after allogeneic hematopoietic cell transplantation: risk factors and clinical outcomesNajla El Jurdi, Ahmad Rayes, Margaret L MacMillan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 2, 2013
Hand grip strength and 2-minute walk test in chronic graft-versus-host disease assessment: analysis from the Chronic GVHD ConsortiumJoseph Pidala, Xiaoyu Chai, Paul Martin, et al.
Pageof 17